Marjan Zare
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marjan Zare has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Azam Faraji
Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
4 shared publications- Ali Semati
Non‐communicable Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
3 shared publications - Alireza Mirahmadizadeh
Non‐communicable Diseases Research Center Shiraz University of Medical Sciences Shiraz Iran
3 shared publications - Azam Faraji
Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications Homeira Vafaei
Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications- Homeira Vafaei
Maternal-fetal medicine Research Center, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 shared publications
Latest Publications
- Open Access
- 17 May 2026
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 24 (3) , 219-230
Serum amyloid A as a diagnostic marker for histologic chorioamnionitis in preterm premature rupture of membranes: A diagnostic accuracy study
Background: Chorioamnionitis is an acute inflammation of the fetal membrane in mothers with preterm premature rupture of the membrane (PPROM). The diagnosis of chorioamnionitis is based on clinical findings; however, laboratory tests may help diagnose the disease. Objective: It aimed to evaluate the accuracy of maternal serum-amyloid A (SAA) protein levels in diagnosing histopathologic chorioamnionitis following PPROM mothers; secondarily, it assessed their accuracy for diagnosing clinical chorioamnionitis. Materials and Methods: In this diagnostic accuracy study, 94 PPROM pregnancies, referred to Namazi, Hafez, and Zeinabiyeh hospitals, Shiraz, Iran, from March 2022 to March 2023 were followed. All placentas were examined for histopathological evidence of chorioamnionitis, and participants were classified into 2 pathologic chorioamnionitis and normal placenta groups. Results: From the 94 participants, 50 (43.20%) were pathologically diagnosed with chorioamnionitis as pathologic chorioamnionitis group, and the remaining 44 (46.80%) belonged to control “normal placenta group”. In addition, 50% (25/50) of women with pathological chorioamnionitis were clinically diagnosed with chorioamnionitis as clinic chorioamnionitis group, and the remaining 50% (25/50) with no clinical signs of chorioamnionitis belonged to their control. Pathologic at-delivery SAA were more in the pathologic chorioamnionitis group compared with normal placenta group; adjusted odds ratio (95% confidence interval); 15.20 (2.62–88.20); the area under curve values (cutoff point, sensitivity, specificity, negative predictive value, positive predictive value, and accuracy) were 0.83 (> 0.54 mg/dl, 95%, 70%, 86%, 88%, and 84%) for pathologic at-delivery SAA. However, clinic at-delivery SAA did not significantly change between clinic chorioamnionitis group and not having clinic chorioamnionitis. A no-clinic chorioamnionitis PPROM mother could be chorioamnionitis one by a 50% chance, even with no clinical sign. Conclusion: Pathologic at-delivery SAA level could be a supplementary test in PPROM mothers. At-delivery SAA serial measurements and long-term evaluation of infants born to these mothers are recommended.
- 17 May 2026
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 24 (3) , 219-230
Open AccessSerum amyloid A as a diagnostic marker for histologic chorioamnionitis in preterm premature rupture of membranes: A diagnostic accuracy study
Background: Chorioamnionitis is an acute inflammation of the fetal membrane in mothers with preterm premature rupture of the membrane (PPROM). The diagnosis of chorioamnionitis is based on clinical findings; however, laboratory tests may help diagnose the disease. Objective: It aimed to evaluate the accuracy of maternal serum-amyloid A (SAA) protein levels in diagnosing histopathologic chorioamnionitis following PPROM mothers; secondarily, it assessed their accuracy for diagnosing clinical chorioamnionitis. Materials and Methods: In this diagnostic accuracy study, 94 PPROM pregnancies, referred to Namazi, Hafez, and Zeinabiyeh hospitals, Shiraz, Iran, from March 2022 to March 2023 were followed. All placentas were examined for histopathological evidence of chorioamnionitis, and participants were classified into 2 pathologic chorioamnionitis and normal placenta groups. Results: From the 94 participants, 50 (43.20%) were pathologically diagnosed with chorioamnionitis as pathologic chorioamnionitis group, and the remaining 44 (46.80%) belonged to control “normal placenta group”. In addition, 50% (25/50) of women with pathological chorioamnionitis were clinically diagnosed with chorioamnionitis as clinic chorioamnionitis group, and the remaining 50% (25/50) with no clinical signs of chorioamnionitis belonged to their control. Pathologic at-delivery SAA were more in the pathologic chorioamnionitis group compared with normal placenta group; adjusted odds ratio (95% confidence interval); 15.20 (2.62–88.20); the area under curve values (cutoff point, sensitivity, specificity, negative predictive value, positive predictive value, and accuracy) were 0.83 (> 0.54 mg/dl, 95%, 70%, 86%, 88%, and 84%) for pathologic at-delivery SAA. However, clinic at-delivery SAA did not significantly change between clinic chorioamnionitis group and not having clinic chorioamnionitis. A no-clinic chorioamnionitis PPROM mother could be chorioamnionitis one by a 50% chance, even with no clinical sign. Conclusion: Pathologic at-delivery SAA level could be a supplementary test in PPROM mothers. At-delivery SAA serial measurements and long-term evaluation of infants born to these mothers are recommended.
- Open Access
- 10 November 2024
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 22 (9) , 727-738
Diagnosis of hydatidiform moles using p57 immunohistochemistry and chromogenic insitu hybridization: A retrospective study
Background: Chromogenic in situ hybridization (CISH) and immunohistochemistry analysis for p57 are ancillary studies discriminating partial hydatidiform mole (PHM), complete hydatidiform mole (CHM), and non-molar hydropic abortion (HA). Objective: It aimed to study CISH with a probe to chromosome 17 (CISH17) and chromosome 2 (CISH2) discriminating chromosomal ploidy of PHM, CHM, and HA; in addition, their surrogacy value in the evaluation of triploid and diploid in product of conception specimens (POCs) was evaluated. Materials and Methods: 44 statistically significant POCs were selected retrospectively. The Kappa agreement coefficients, sensitivity, specificity, and accuracy with 95% confidence interval (95% CI) were reported. Results: PHM, CHM, and HA were diagnosed to be 23, 17, and 3 cases based on both CISH2 and CISH17 resulting in their complete discrimination between PHM and HA (23 vs. 3). The Kappa agreement coefficient was 95.4% (p < 0.001) when diagnosing the PHM (23), CHM (20), and HA (1). In addition, the accuracy, sensitivity, and specificity were 95.26% (95% CI: 84.25–99.38), 100% (95% CI: 85.18–100), and 95% (95% CI: 76.18–99.88), respectively. The power analysis on CISH2 and CISH17 tests discriminating between triploid and diploid in POCs was estimated to be 100%. Conclusion: Based on the current finding, CISH2 and CISH17 enjoyed perfect agreement in diagnosing chromosomal ploidy; in addition, their absolute power discriminating between triploid and diploid revealed that they could be used as surrogate markers for ploidy. Prospective studies on fresh specimens are suggested comparing the CISH method’s accuracy with flow cytometry karyotyping and fluorescence in situ hybridization. Key words: Hydatidiform mole, CISH protein, Human, Pathology, Clinical.
- 10 November 2024
- Published by Knowledge E DMCC in International Journal of Reproductive BioMedicine (IJRM)
- Vol. 22 (9) , 727-738
Open AccessDiagnosis of hydatidiform moles using p57 immunohistochemistry and chromogenic insitu hybridization: A retrospective study
Background: Chromogenic in situ hybridization (CISH) and immunohistochemistry analysis for p57 are ancillary studies discriminating partial hydatidiform mole (PHM), complete hydatidiform mole (CHM), and non-molar hydropic abortion (HA). Objective: It aimed to study CISH with a probe to chromosome 17 (CISH17) and chromosome 2 (CISH2) discriminating chromosomal ploidy of PHM, CHM, and HA; in addition, their surrogacy value in the evaluation of triploid and diploid in product of conception specimens (POCs) was evaluated. Materials and Methods: 44 statistically significant POCs were selected retrospectively. The Kappa agreement coefficients, sensitivity, specificity, and accuracy with 95% confidence interval (95% CI) were reported. Results: PHM, CHM, and HA were diagnosed to be 23, 17, and 3 cases based on both CISH2 and CISH17 resulting in their complete discrimination between PHM and HA (23 vs. 3). The Kappa agreement coefficient was 95.4% (p < 0.001) when diagnosing the PHM (23), CHM (20), and HA (1). In addition, the accuracy, sensitivity, and specificity were 95.26% (95% CI: 84.25–99.38), 100% (95% CI: 85.18–100), and 95% (95% CI: 76.18–99.88), respectively. The power analysis on CISH2 and CISH17 tests discriminating between triploid and diploid in POCs was estimated to be 100%. Conclusion: Based on the current finding, CISH2 and CISH17 enjoyed perfect agreement in diagnosing chromosomal ploidy; in addition, their absolute power discriminating between triploid and diploid revealed that they could be used as surrogate markers for ploidy. Prospective studies on fresh specimens are suggested comparing the CISH method’s accuracy with flow cytometry karyotyping and fluorescence in situ hybridization. Key words: Hydatidiform mole, CISH protein, Human, Pathology, Clinical.
- Open Access
- 30 December 2022
- Published by Salvia Medical Sciences Ltd in Galen Medical Journal
- Vol. 11, e2395
Hypertensive Pregnancy Disorders and Lipid Profiles: A Cohort Study
Background: The global prevalence of hypertensive pregnancy disorders (HPDs) is 5.2%-8.2%. Lipid profiles made up of triglycerides (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL), and high-density lipoprotein-cholesterol (HDL) could affect the arterial vessel wall leading to HPDs. Preeclampsia (PE), among the most severe maternal-fetal HPDs, has affected 0.2%-9.2% of all pregnancies. The current study aimed to investigate the role of lipid profiles in predicting PE in the first and early third trimesters of pregnancy. Material and Method: A large-scale prospective cohort study was conducted from early pregnancy onward in a normal population in the south of Iran. Fasting blood samples were examined for TG, TC, HDL, and LDL, as well as LDL/HDL ratio levels in the first and early third trimesters. Result: Of 486 pregnant women, 37 women developed HPDs, of which 20 (54%) developed PE. In the PE group, the levels of serum lipid profiles, including TG, TC, LDL, and HDL, significantly raised with gestational age (P<0.05). After adjusting for maternal age and body mass index, TG, TC, LDL, and LDL/HDL ratio levels were associated with a higher risk of PE (odds ratio [OR]=1.025, 1.035, 1.03, 2.08, and 1.026, 1.044, 1.03, 2.14, P<0.001) regarding the first and early third trimesters, respectively. The optimum cut-off points for TG, TC, LDL, and LDL/HDL ratios predicting PE were estimated to be 180.5 mg/dl, 197.5 mg/dl, 136 mg/dl, and 3.66 in the first, and 220 mg/dl, 204 mg/dl, 155.5 mg/dl, and 3.97 in the early third trimesters. Conclusion: Dyslipidemia during pregnancy may help predict PE development that can be sustained with lipid-lowering drugs. [GMJ.2022;11:e2395]
- 30 December 2022
- Published by Salvia Medical Sciences Ltd in Galen Medical Journal
- Vol. 11, e2395
Open AccessHypertensive Pregnancy Disorders and Lipid Profiles: A Cohort Study
Background: The global prevalence of hypertensive pregnancy disorders (HPDs) is 5.2%-8.2%. Lipid profiles made up of triglycerides (TG), total cholesterol (TC), low-density lipoprotein-cholesterol (LDL), and high-density lipoprotein-cholesterol (HDL) could affect the arterial vessel wall leading to HPDs. Preeclampsia (PE), among the most severe maternal-fetal HPDs, has affected 0.2%-9.2% of all pregnancies. The current study aimed to investigate the role of lipid profiles in predicting PE in the first and early third trimesters of pregnancy. Material and Method: A large-scale prospective cohort study was conducted from early pregnancy onward in a normal population in the south of Iran. Fasting blood samples were examined for TG, TC, HDL, and LDL, as well as LDL/HDL ratio levels in the first and early third trimesters. Result: Of 486 pregnant women, 37 women developed HPDs, of which 20 (54%) developed PE. In the PE group, the levels of serum lipid profiles, including TG, TC, LDL, and HDL, significantly raised with gestational age (P<0.05). After adjusting for maternal age and body mass index, TG, TC, LDL, and LDL/HDL ratio levels were associated with a higher risk of PE (odds ratio [OR]=1.025, 1.035, 1.03, 2.08, and 1.026, 1.044, 1.03, 2.14, P<0.001) regarding the first and early third trimesters, respectively. The optimum cut-off points for TG, TC, LDL, and LDL/HDL ratios predicting PE were estimated to be 180.5 mg/dl, 197.5 mg/dl, 136 mg/dl, and 3.66 in the first, and 220 mg/dl, 204 mg/dl, 155.5 mg/dl, and 3.97 in the early third trimesters. Conclusion: Dyslipidemia during pregnancy may help predict PE development that can be sustained with lipid-lowering drugs. [GMJ.2022;11:e2395]
- 13 July 2022
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 50 (9) , 1273
Reply to: Aspirin for the prevention of preeclampsia
Article Reply to: aspirin for the prevention of preeclampsia was published on August 3, 2022 in the journal Journal of Perinatal Medicine (volume 0, issue 0).
- 13 July 2022
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 50 (9) , 1273
Reply to: Aspirin for the prevention of preeclampsia
Article Reply to: aspirin for the prevention of preeclampsia was published on August 3, 2022 in the journal Journal of Perinatal Medicine (volume 0, issue 0).
- 23 June 2022
- Published by Wiley in Respirology
- Vol. 27 (9) , 758-766
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Background and objective: Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients.Methods: In this multi‐arm randomized clinical trial conducted between 9 April 2021 and 20 May 2021, a total of 393 patients with reverse transcription‐PCR‐confirmed COVID‐19 infection and mild symptoms were enrolled. Subjects were randomized in a 1:1:1 ratio to receive single‐dose ivermectin (12 mg), double‐dose ivermectin (24 mg) or placebo. The primary outcome was need for hospitalization.Results: There was no significant difference in the proportion of subjects who required hospitalization between the placebo and single‐dose ivermectin groups (absolute difference in the proportions: −2.3 [95% CI = −8.5, 4.1]) and between the placebo and double‐dose ivermectin groups (absolute difference in the proportions: −3.9 [95% CI = −9.8, 2.2]). The odds of differences in mean change in severity score between single‐dose ivermectin and placebo groups (ORdifference = 1.005 [95% CI: 0.972, 1.040]; p = 0.762) and double‐dose ivermectin and placebo groups (ORdifference = 1.010 [95% CI: 0.974, 1.046]; p = 0.598) were not statistically significant. None of the six adverse events (including mild dermatitis, tachycardia and hypertension) were serious and required extra action.Conclusion: Single‐dose and double‐dose ivermectin early treatment were not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID‐19.
- 23 June 2022
- Published by Wiley in Respirology
- Vol. 27 (9) , 758-766
Efficacy of single‐dose and double‐dose ivermectin early treatment in preventing progression to hospitalization in mild COVID‐19: A multi‐arm, parallel‐group randomized, double‐blind, placebo‐controlled trial
Background and objective: Ivermectin is a known anti‐parasitic agent that has been investigated as an antiviral agent against coronavirus disease 2019 (COVID‐19). This study aimed to evaluate the efficacy of ivermectin in mild COVID‐19 patients.Methods: In this multi‐arm randomized clinical trial conducted between 9 April 2021 and 20 May 2021, a total of 393 patients with reverse transcription‐PCR‐confirmed COVID‐19 infection and mild symptoms were enrolled. Subjects were randomized in a 1:1:1 ratio to receive single‐dose ivermectin (12 mg), double‐dose ivermectin (24 mg) or placebo. The primary outcome was need for hospitalization.Results: There was no significant difference in the proportion of subjects who required hospitalization between the placebo and single‐dose ivermectin groups (absolute difference in the proportions: −2.3 [95% CI = −8.5, 4.1]) and between the placebo and double‐dose ivermectin groups (absolute difference in the proportions: −3.9 [95% CI = −9.8, 2.2]). The odds of differences in mean change in severity score between single‐dose ivermectin and placebo groups (ORdifference = 1.005 [95% CI: 0.972, 1.040]; p = 0.762) and double‐dose ivermectin and placebo groups (ORdifference = 1.010 [95% CI: 0.974, 1.046]; p = 0.598) were not statistically significant. None of the six adverse events (including mild dermatitis, tachycardia and hypertension) were serious and required extra action.Conclusion: Single‐dose and double‐dose ivermectin early treatment were not superior to the placebo in preventing progression to hospitalization and improving clinical course in mild COVID‐19.
- Open Access
- 30 May 2022
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2022, 1-12
Spatiotemporal Study of COVID-19 in Fars Province, Iran, October-November 2020: Establishment of Early Warning System
Background. Using time series and spatiotemporal analyses, this study aimed to establish an Early Warning System (EWS) for COVID-19 in Fars province Iran. Methods. A EWS was conducted on (i) daily basis city-level time series data including 53 554 cases recorded during 18 February–30 September 2020, which were applied to forecast COVID-19 cases during 1 October–14 November 2020, and (ii) the spatiotemporal analysis, which was conducted on the forecasted cases to predict spatiotemporal outbreaks of COVID-19. Results. A total of 55 369 cases were forecasted during 1 October–14 November 2020, most of which (26.9%) occurred in Shiraz. In addition, 65.80% and 34.20% of the cases occurred in October and November, respectively. Four significant spatiotemporal outbreaks were predicted, with the Most Likely Cluster (MLC) occurring in ten cities during 2–22 October ( for all). Moreover, subgroup analysis demonstrated that Zarrindasht was the canon of the epidemic on 6 October ( ). As a part of EWS, the epidemic was triggered from Jahrom, involving the MLC districts in the center, west, and south parts of the province. Then, it showed a tendency to move towards Zarrindasht in the south and progress to Lar in the southernmost part. Afterwards, it simultaneously progressed to Fasa and Sepidan in the central and northwestern parts of the province, respectively. Conclusion. EWS, which was established based on the current protocol, alarmed policymakers and health managers on the progression of the epidemic and on where and when to implement medical facilities. These findings can be used to tailor province-level policies to servile the ongoing epidemic in the area; however, governmental level effort is needed to control the epidemic at a larger scale in the future.
- 30 May 2022
- Published by Hindawi Limited in Canadian Journal of Infectious Diseases and Medical Microbiology
- Vol. 2022, 1-12
Open AccessSpatiotemporal Study of COVID-19 in Fars Province, Iran, October-November 2020: Establishment of Early Warning System
Background. Using time series and spatiotemporal analyses, this study aimed to establish an Early Warning System (EWS) for COVID-19 in Fars province Iran. Methods. A EWS was conducted on (i) daily basis city-level time series data including 53 554 cases recorded during 18 February–30 September 2020, which were applied to forecast COVID-19 cases during 1 October–14 November 2020, and (ii) the spatiotemporal analysis, which was conducted on the forecasted cases to predict spatiotemporal outbreaks of COVID-19. Results. A total of 55 369 cases were forecasted during 1 October–14 November 2020, most of which (26.9%) occurred in Shiraz. In addition, 65.80% and 34.20% of the cases occurred in October and November, respectively. Four significant spatiotemporal outbreaks were predicted, with the Most Likely Cluster (MLC) occurring in ten cities during 2–22 October ( for all). Moreover, subgroup analysis demonstrated that Zarrindasht was the canon of the epidemic on 6 October ( ). As a part of EWS, the epidemic was triggered from Jahrom, involving the MLC districts in the center, west, and south parts of the province. Then, it showed a tendency to move towards Zarrindasht in the south and progress to Lar in the southernmost part. Afterwards, it simultaneously progressed to Fasa and Sepidan in the central and northwestern parts of the province, respectively. Conclusion. EWS, which was established based on the current protocol, alarmed policymakers and health managers on the progression of the epidemic and on where and when to implement medical facilities. These findings can be used to tailor province-level policies to servile the ongoing epidemic in the area; however, governmental level effort is needed to control the epidemic at a larger scale in the future.
- 27 May 2022
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 50 (9) , 1264-1270
The effect of 150 and 80 mg doses of aspirin on preventing preterm birth in high-risk pregnant women
Objectives: Preterm birth (PTB) is the common cause of neonatal mortality nationwide. The present study aimed to evaluate the efficacy of different doses of aspirin in preventing PTB in high-risk pregnant women. As secondary outcomes, other perinatal complications were compared. Methods: This double-blind randomized clinical trial was conducted on high-risk pregnant women with impaired placental perfusion diagnosed in the first trimester of pregnancy referring to the perinatal centers affiliated to Shiraz university of Medical Sciences between February 2020 and March 2021. The subjects were randomly divided in two groups administered with 150 or 80 mg aspirin every night from 11 to 13+6 weeks until 36 weeks or delivery. This study is registered in the Iranian Registry of Clinical Trials (IRCT20140317017035N6; http://www.irct.ir/). Univariate and multiple logistic regressions were applied using SPSS 22. Results: A total of 101 subjects received 80 mg aspirin and 89 ones received 150 mg aspirin. The results of multiple analysis revealed a significantly lower odds of PTB (OR 0.4 (0.19, 0.99)) in the 150 mg group compared to the 80 mg group. As secondary outcomes, preeclampsia (PEC) and PEC with severe features (PECsf) were lower (OR 0.2 (0.06, 0.82) and 0.1 (0.01, 0.92), respectively); however, fetal age and neonatal weight were higher in the 150 mg group (OR 1.2 (1.04, 1.33) and 1.001 (1–1.001), respectively). Conclusions: The study findings indicated that, compared with 80 mg of aspirin, taking 150 mg of aspirin reduced PTB and perinatal complications in high risk pregnant women.
- 27 May 2022
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 50 (9) , 1264-1270
The effect of 150 and 80 mg doses of aspirin on preventing preterm birth in high-risk pregnant women
Objectives: Preterm birth (PTB) is the common cause of neonatal mortality nationwide. The present study aimed to evaluate the efficacy of different doses of aspirin in preventing PTB in high-risk pregnant women. As secondary outcomes, other perinatal complications were compared. Methods: This double-blind randomized clinical trial was conducted on high-risk pregnant women with impaired placental perfusion diagnosed in the first trimester of pregnancy referring to the perinatal centers affiliated to Shiraz university of Medical Sciences between February 2020 and March 2021. The subjects were randomly divided in two groups administered with 150 or 80 mg aspirin every night from 11 to 13+6 weeks until 36 weeks or delivery. This study is registered in the Iranian Registry of Clinical Trials (IRCT20140317017035N6; http://www.irct.ir/). Univariate and multiple logistic regressions were applied using SPSS 22. Results: A total of 101 subjects received 80 mg aspirin and 89 ones received 150 mg aspirin. The results of multiple analysis revealed a significantly lower odds of PTB (OR 0.4 (0.19, 0.99)) in the 150 mg group compared to the 80 mg group. As secondary outcomes, preeclampsia (PEC) and PEC with severe features (PECsf) were lower (OR 0.2 (0.06, 0.82) and 0.1 (0.01, 0.92), respectively); however, fetal age and neonatal weight were higher in the 150 mg group (OR 1.2 (1.04, 1.33) and 1.001 (1–1.001), respectively). Conclusions: The study findings indicated that, compared with 80 mg of aspirin, taking 150 mg of aspirin reduced PTB and perinatal complications in high risk pregnant women.
- Open Access
- 1 May 2022
- Vol. 47 (3) , 219-226
Epidemiological Study of Infection and Death Due to COVID-19 in Fars Province, Iran, From February to September 2020
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has entered our lives with the fear of outbreak, death, and recurrence. Our objective in this study is to evaluate the epidemiological features of Coronavirus Disease 2019 (COVID-19) infection and death in Fars province, Iran. Methods: A cross-sectional study was conducted from February 18th to September 30th, 2020, where age, history of underlying diseases, sex, community-wide quarantine, nationality, close contact, pregnancy, medical staff job, traveling, and residency were compared between alive and deceased groups. Data were analyzed using IBM SPSS software, version 22.0, and the significance level was set at 0.05. Results: Regarding 57958 new cases of COVID-19, the basic reproduction number (R-0) was estimated as 2.8, requiring a minimum of 65% immunization to reach herd immunity. Moreover, an R-0=0.36 was required to reach the endemic state in the region. The incidence, mortality, fatality, and recurrence rates of COVID-19 were estimated as 1347.9 per 100,000 dwellers, 209.5 per 1000,000 dwellers, 1.6 %, and 3.1 per 100,000 dwellers, respectively. Age, history of underlying diseases, urban residency, and the male sex were significantly higher in the deceased group (OR=1.09, 5.48, 1.24, and 1.32; All Ps<0.001, <0.001, 0.005, and <0.001, respectively). In addition, the recurrence rate among positive cases was estimated as 0.23% with a median +/- inter-quartile range equal to 84 +/- 46.25 days. Community-wide quarantine was shown to be a protective factor for death due to COVID-19 (OR=0.58, P=0.005). Conclusion: Community-wide quarantine blocks the transmission of COVID-19 effectively. COVID-19 enjoys no solid immunity. History of underlying diseases, the male sex, urban residency, and age were among the most significant causes of death due to COVID-19. Further investigations are recommended on the genetic structure of SARS-CoV-2, treatments, and vaccination.
- 1 May 2022
- Vol. 47 (3) , 219-226
Open AccessEpidemiological Study of Infection and Death Due to COVID-19 in Fars Province, Iran, From February to September 2020
Background: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has entered our lives with the fear of outbreak, death, and recurrence. Our objective in this study is to evaluate the epidemiological features of Coronavirus Disease 2019 (COVID-19) infection and death in Fars province, Iran. Methods: A cross-sectional study was conducted from February 18th to September 30th, 2020, where age, history of underlying diseases, sex, community-wide quarantine, nationality, close contact, pregnancy, medical staff job, traveling, and residency were compared between alive and deceased groups. Data were analyzed using IBM SPSS software, version 22.0, and the significance level was set at 0.05. Results: Regarding 57958 new cases of COVID-19, the basic reproduction number (R-0) was estimated as 2.8, requiring a minimum of 65% immunization to reach herd immunity. Moreover, an R-0=0.36 was required to reach the endemic state in the region. The incidence, mortality, fatality, and recurrence rates of COVID-19 were estimated as 1347.9 per 100,000 dwellers, 209.5 per 1000,000 dwellers, 1.6 %, and 3.1 per 100,000 dwellers, respectively. Age, history of underlying diseases, urban residency, and the male sex were significantly higher in the deceased group (OR=1.09, 5.48, 1.24, and 1.32; All Ps<0.001, <0.001, 0.005, and <0.001, respectively). In addition, the recurrence rate among positive cases was estimated as 0.23% with a median +/- inter-quartile range equal to 84 +/- 46.25 days. Community-wide quarantine was shown to be a protective factor for death due to COVID-19 (OR=0.58, P=0.005). Conclusion: Community-wide quarantine blocks the transmission of COVID-19 effectively. COVID-19 enjoys no solid immunity. History of underlying diseases, the male sex, urban residency, and age were among the most significant causes of death due to COVID-19. Further investigations are recommended on the genetic structure of SARS-CoV-2, treatments, and vaccination.
- Open Access
- 14 January 2022
- Published by PAGEPress Publications in Geospatial Health
- Vol. 17 (s1)
Spatial epidemiology and meteorological risk factors of COVID-19 in Fars Province, Iran
This study aimed at detecting space-time clusters of COVID-19 cases in Fars Province, Iran and at investigating their potential association with meteorological factors, such as temperature, precipitation and wind velocity. Time-series data including 53,554 infected people recorded in 26 cities from 18 February to 30 September 2020 together with 5876 meteorological records were subjected to the analysis. Applying a significance level of P<0.05, the analysis of space-time distribution of COVID-19 resulted in nine significant outbreaks within the study period. The most likely cluster occurred from 27 March to 13 July 2020 and contained 11% of the total cases with eight additional, secondary clusters. We found that the COVID-19 incidence rate was affected by high temperature (OR=1.64; 95% CI: 1.44-1.87), while precipitation and wind velocity had less effect (OR=0.84; 95% CI: 0.75-0.89 and OR=0.27; 95% CI: 0.14-0.51), respectively.
- 14 January 2022
- Published by PAGEPress Publications in Geospatial Health
- Vol. 17 (s1)
Open AccessSpatial epidemiology and meteorological risk factors of COVID-19 in Fars Province, Iran
This study aimed at detecting space-time clusters of COVID-19 cases in Fars Province, Iran and at investigating their potential association with meteorological factors, such as temperature, precipitation and wind velocity. Time-series data including 53,554 infected people recorded in 26 cities from 18 February to 30 September 2020 together with 5876 meteorological records were subjected to the analysis. Applying a significance level of P<0.05, the analysis of space-time distribution of COVID-19 resulted in nine significant outbreaks within the study period. The most likely cluster occurred from 27 March to 13 July 2020 and contained 11% of the total cases with eight additional, secondary clusters. We found that the COVID-19 incidence rate was affected by high temperature (OR=1.64; 95% CI: 1.44-1.87), while precipitation and wind velocity had less effect (OR=0.84; 95% CI: 0.75-0.89 and OR=0.27; 95% CI: 0.14-0.51), respectively.
- 31 December 2021
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 51 (2) , 269-276
Comparison of in-hospital mortality of COVID-19 between pregnant and non-pregnant women infected with SARS-CoV-2: a historical cohort study
Objectives: This study aimed to compare pregnant and non-pregnant women infected with SARS-CoV-2 disease (COVID-19) in terms of in-hospital mortality. Methods: This historical cohort study was conducted on hospitalized women of reproductive ages (15–49 years) infected with SARS-CoV-2 in Fars province, Iran during 15 March 2019–10 May 2021. Results: Out of the 5,322 patients, 330 were pregnant. The fatality rate of SARS-CoV-2 was 1.2% amongst pregnant women and 3.5% amongst non-pregnant ones. Pregnant and non-pregnant women reported the same history of smoking, opium use, previous COVID-19 infection, vaccination against SARS-CoV-2, and COVID-19 symptoms (p>0.05 for all). However, the pregnant women were younger and had fewer underlying diseases (p<0.001 for both). The results revealed no significant difference between the two groups regarding in-hospital clinical manifestations including the number of days after the onset of COVID-19 symptoms, mechanical ventilation, and long involvement (cRR; 95% CI=0.99 (0.96–1.02), 1.18 (0.72–2.02), and 0.95 (0.88–1.02), respectively). Nonetheless, Intensive Care Unit (ICU) admission was significantly higher in pregnant women (cRR; 95% CI=2.37(1.85–3.02)). After adjusting for age, history of underlying diseases, and ICU admission, pregnant women showed lower in-hospital mortality due to COVID-19 compared to non-pregnant women (aRR; 95% CI=0.32 (0.12–0.87)). Conclusions: Based on the current study findings, pregnant women showed lower in-hospital mortality due to COVID-19 compared to non-pregnant ones. Nevertheless, they should follow the same recommendations as non-pregnant women, avoiding exposure to the virus and receiving medical treatment and vaccination. Further studies are recommended to address the follow-up of recovered pregnant women, their babies, and puerperium.
- 31 December 2021
- Published by Walter de Gruyter GmbH in Journal of Perinatal Medicine
- Vol. 51 (2) , 269-276
Comparison of in-hospital mortality of COVID-19 between pregnant and non-pregnant women infected with SARS-CoV-2: a historical cohort study
Objectives: This study aimed to compare pregnant and non-pregnant women infected with SARS-CoV-2 disease (COVID-19) in terms of in-hospital mortality. Methods: This historical cohort study was conducted on hospitalized women of reproductive ages (15–49 years) infected with SARS-CoV-2 in Fars province, Iran during 15 March 2019–10 May 2021. Results: Out of the 5,322 patients, 330 were pregnant. The fatality rate of SARS-CoV-2 was 1.2% amongst pregnant women and 3.5% amongst non-pregnant ones. Pregnant and non-pregnant women reported the same history of smoking, opium use, previous COVID-19 infection, vaccination against SARS-CoV-2, and COVID-19 symptoms (p>0.05 for all). However, the pregnant women were younger and had fewer underlying diseases (p<0.001 for both). The results revealed no significant difference between the two groups regarding in-hospital clinical manifestations including the number of days after the onset of COVID-19 symptoms, mechanical ventilation, and long involvement (cRR; 95% CI=0.99 (0.96–1.02), 1.18 (0.72–2.02), and 0.95 (0.88–1.02), respectively). Nonetheless, Intensive Care Unit (ICU) admission was significantly higher in pregnant women (cRR; 95% CI=2.37(1.85–3.02)). After adjusting for age, history of underlying diseases, and ICU admission, pregnant women showed lower in-hospital mortality due to COVID-19 compared to non-pregnant women (aRR; 95% CI=0.32 (0.12–0.87)). Conclusions: Based on the current study findings, pregnant women showed lower in-hospital mortality due to COVID-19 compared to non-pregnant ones. Nevertheless, they should follow the same recommendations as non-pregnant women, avoiding exposure to the virus and receiving medical treatment and vaccination. Further studies are recommended to address the follow-up of recovered pregnant women, their babies, and puerperium.